<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584983</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0916</org_study_id>
    <nct_id>NCT04584983</nct_id>
  </id_info>
  <brief_title>Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration</brief_title>
  <official_title>Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Usual versus Reduced Lipid Intake on&#xD;
      Unbound Bilirubin Levels, Brainstem Auditory Evoked Potentials, and neurodevelopmental&#xD;
      Outcome at 2 Years in Extremely Preterm Infants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with unbound bilirubin (UB) concentration greater than 40 nM/L</measure>
    <time_frame>within first 14 days of life</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average unbound bilirubin (UB) concentration</measure>
    <time_frame>within first 14 days of life</time_frame>
    <description>6 UB measurements will be taken per participant .Average of the 6 readings will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a prolonged brain stem auditory-evoked response (BAER) V latency</measure>
    <time_frame>34-36 weeks post menstrual age(PMA)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean UB concentration</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with UB measurements greater than 40 nM/L</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak UB concentration</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total unbound free fatty acids (FFA)</measure>
    <time_frame>within first 14 days of life</time_frame>
    <description>6 FFA measurements will be taken for each participant.Average of the 6 readings will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak total unbound free fatty acids (FFA)</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak total serum bilirubin</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Direct bilirubin greater than 1.5 mg/dL</measure>
    <time_frame>Before discharge (discharge is on average 3 months after birth)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of protein given to participant in grams per kilograms per day</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of carbohydrates given to participant in grams per kilograms per day</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of fats given to participant in grams per kilograms per day</measure>
    <time_frame>within first 14 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight(grams/kilogram/day)</measure>
    <time_frame>birth,day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight(grams/kilogram/day)</measure>
    <time_frame>birth,post menstrual age 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with Perinatal and hospital acquired sepsis episodes</measure>
    <time_frame>birth until discharge ( discharge will be about 3 months post birth)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who died</measure>
    <time_frame>24 months PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with neurodevelopmental impairment</measure>
    <time_frame>24 months PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hearing loss</measure>
    <time_frame>24 months PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cerebral palsy</measure>
    <time_frame>24 months PMA</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bilirubin Encephalopathy</condition>
  <arm_group>
    <arm_group_label>usual prescribed intralipid (UL) regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>restricted prescribed intralipid (RL) regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual prescribed intralipid (UL) regimen</intervention_name>
    <description>Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice</description>
    <arm_group_label>usual prescribed intralipid (UL) regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>restricted prescribed intralipid (RL) regimen</intervention_name>
    <description>Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).</description>
    <arm_group_label>restricted prescribed intralipid (RL) regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  no major congenital anomaly or overt nonbacterial infection&#xD;
&#xD;
          -  mother has consented to inclusion of the infant for the Neonatal Research Network&#xD;
             (NRN) Cycled Phototherapy Trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has received Intralipid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>27 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay N Fleig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsay N Fleig, MD</last_name>
    <phone>(713) 500-6422</phone>
    <email>Lindsay.N.Fleig@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily K Stephens</last_name>
    <phone>(713) 500-5734</phone>
    <email>Emily.K.Stephens@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay N Fleig, MD</last_name>
      <phone>713-500-6422</phone>
      <email>Lindsay.N.Fleig@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Stephens</last_name>
      <phone>(713) 500-5734</phone>
      <email>Emily.K.Stephens@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Lindsay Fleig Holzapfel, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>preterm</keyword>
  <keyword>bilirubin</keyword>
  <keyword>lipid emulsions</keyword>
  <keyword>unbound bilirubin</keyword>
  <keyword>unbound free fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Kernicterus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

